Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

PURPOSE: Cyclin D/CDK4/6 is critical in controlling the G(1) to S checkpoint. CCND, the gene encoding cyclin D, is known to be amplified in a variety of solid tumors. Palbociclib is an oral CDK4/6 inhibitor, approved in advanced breast cancer in combination with endocrine therapy. We explored the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Amy S., Hong, Fangxin, Finn, Richard S., DeMichele, Angela M., Mitchell, Edith P., Zwiebel, James, Arnaldez, Fernanda I., Gray, Robert J., Wang, Victoria, McShane, Lisa M., Rubinstein, Larry V., Patton, David, Williams, P. Mickey, Hamilton, Stanley R., Copur, Mehmet S., Kasbari, Samer S., Thind, Ravneet, Conley, Barbara A., Arteaga, Carlos L., O'Dwyer, Peter J., Harris, Lyndsay N., Chen, Alice P., Flaherty, Keith T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102836/
https://www.ncbi.nlm.nih.gov/pubmed/36853016
http://dx.doi.org/10.1158/1078-0432.CCR-22-2150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102836/
https://www.ncbi.nlm.nih.gov/pubmed/36853016
http://dx.doi.org/10.1158/1078-0432.CCR-22-2150

Ejemplares similares